In this study, we aimed to add to the existing understanding of peripheral APP expression in FXS by quantifying peripheral APP metabolite and processing enzyme expression in individuals with FXS compared to typically developing controls (TDC). The gene discussed is APP; the disease is fragile X syndrome.